Semaglutide Recall: Boothwyn Pharmacy 2.5 mg/mL injection
Announced 2025-09-10 · FDA
FDA is recalling Boothwyn Pharmacy LLC's Semaglutide, 2.5 mg/mL injection (4 mL vials) because the drug is subpotent. Approximately 648 vials were distributed nationwide. The recall numbers are 03202025@2, 03202025@3, and 03202025@4 with a BUD of 07/18/2025.
| Brand | Boothwyn Pharmacy LLC |
|---|---|
| Product | Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy |
| Reason | Subpotent Drug |
| Severity | moderate |
| Units affected | 186 |
| Distribution | U.S. Nationwide |
| Agency | FDA |
WHAT YOU SHOULD DO
- Do not use any recalled injections.
- If you have any of the affected vials, contact Boothwyn Pharmacy LLC to arrange return, disposal, or replacement, and keep packaging with the recall numbers 03202025@2, 03202025@3, or 03202025@4 and the BUD date 07/18/2025.
- If you have used the product, discuss potential risks with your healthcare provider and report any adverse effects to the FDA MedWatch program.
How to identify the recalled item
| Lot / date codes | 03202025@2, 03202025@3 and 03202025@4 BUD 07/18/2025 |
|---|---|
| Lot / date codes | 03202025@9 BUD 07/18/2025 |
These are the identifiers FDA published for this recall. Most recall notices list no UPC or model number at all — if the code on your item is not shown here, that does not mean the item is excluded. Check the official notice, or contact the company.
Other semaglutide recalls
- Semaglutide Recall: Northwest Compounders Lot 01-27-2026@14S.5 · 2026-04-22
- Semaglutide Recall: Nomida Lot 241113 and Lot 250103 · 2026-03-11
- Semaglutide Recall: Harbin Jixianglong Biotech CP-030-20250711 · 2026-03-11
- Semaglutide Recall: Wegovy Injection Pens · 2026-01-07
- Semaglutide Recall: ProRx 2 mL Multidose Vial · 2025-11-05
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.